High incidence of candidaemia in a nationwide cohort: Underlying diseases, risk factors and mortality
Open Access
- 1 November 2018
- journal article
- research article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 76, 58-63
Abstract
No abstract availableKeywords
Funding Information
- Amplyx
- Basilea
- Cidara
- F2G
- Gilead
- Astellas
- MSD
- Pfizer
- T2Biosystems
- astra zeneca
- Horizon Pharmaceuticals
This publication has 29 references indexed in Scilit:
- Concepts of comorbidities, multiple morbidities, complications, and their clinical epidemiologic analogsClinical Epidemiology, 2013
- Epidemiology of Candidemia in Latin America: A Laboratory-Based SurveyPLOS ONE, 2013
- Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with FungemiaJournal of Clinical Microbiology, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- Evaluation of "Candida score" in critically ill patients: a prospective, multicenter, observational, cohort studyAnnals of Intensive Care, 2011
- National Surveillance of Fungemia in Denmark (2004 to 2009)Journal of Clinical Microbiology, 2011
- Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance RegistryClinical Infectious Diseases, 2009
- Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibilityClinical Microbiology and Infection, 2008
- Active Surveillance of Candidemia, AustraliaEmerging Infectious Diseases, 2006
- A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization*Critical Care Medicine, 2006